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MicroRNAs (miRNAs) have emerged as a new class of posttranscriptional regulators ofmany cardiac and vascular diseases.They are
a class of small, noncoding RNAs that contributes crucial roles typically through binding of the 3󸀠-untranslated region of mRNA. A
singlemiRNAmay influence several signaling pathways associatedwith cardiac remodeling by targetingmultiple genes. Pulmonary
hypertension (PH) is a rare disorder characterized by progressive obliteration of pulmonary (micro) vasculature that results in
elevated vascular resistance, leading to right ventricular hypertrophy (RVH) and RV failure.The pathology of PH involves vascular
cell remodeling including pulmonary arterial endothelial cell (PAEC) dysfunction and pulmonary arterial smooth muscle cell
(PASMC) proliferation.There is no cure for this disease.Thus, novel intervention pathways that govern PH induced RVHmay result
in new treatment modalities. Current therapies are limited to reverse the vascular remodeling. Recent studies have demonstrated
the roles of various miRNAs in the pathogenesis of PH and pulmonary disorders. This review provides an overview of recent
discoveries on the role of miRNAs in the pathogenesis of PH and discusses the potential for miRNAs as therapeutic targets and
biomarkers of PH at clinical setting.
1. Introduction
Pulmonary hypertension (PH) is predominantly defined by
a mean pulmonary artery pressure at rest greater than or
equal to 25mmHg. It is an enigmatic vascular disease and
the pathogenesis of PH is multifactorial of origin and, hence,
is categorized as idiopathic type [1–4]. As PH develops in a
wide variety of clinical circumstances and is associated with
diverse histological manifestations, a classification system is
developed [5, 6].TheDanaPoint expert grouphas published a
consensus of PH classification based on pathology, survival,
natural history/epidemiology, etiology, and response to the
treatment [5]. Among them, one of the most classical types is
pulmonary arterial hypertension (PAH). PAH specifies that
the disease primarily restricted to the pulmonary arterioles,
a typical characteristic which shows an elevated pulmonary
arterial pressure [2, 3].The pathological consequence of PAH
is the structural remodeling of pulmonary arteries (PA),
where increased proliferation of pulmonary artery smooth
muscle cells (PASMC) and dysfunction of pulmonary artery
endothelial cells (PAEC) occur in the vascular bed [7–9].
The morphological changes consist of hypertrophy of the
tunica media, multicellular vascular lesions which obstruct
and obliterate pulmonary arterioles leading to intimal thick-
ening. The obstructed vessels limit the blood flow via PA
and increase right ventricular afterload leading to right
ventricular hypertrophy (RVH) and RV dysfunction [10–12].
At molecular level, it is believed that the remodeling events
in PH demand the participation of all cell-types present in
the pulmonary arteries and that influence the pathological
manifestation in the pulmonary vessel wall. The contributing
factors that influence the remodeling process are hypoxic
state, inflammation, vessel injury, and oxidative stress in the
pulmonary vessels. As all forms of PH have in common
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Figure 1: miRNA biogenesis. The miRNAs are transcribed by RNA polymerase II as primary transcript of miRNA (pri-miRNA). The pri-
miRNA is the cleaved by RNase III enzyme, Drosha, along with several cofactors including DGCR8 and produces the stem-loop precursor
miRNA (pre-miRNA).The pre-miRNA is then exported out of the nucleus by Exportin-5 to the cytoplasm. In the cytoplasm, the pre-miRNA
is diced-up by Dicer resulting miRNA duplex, ∼22 nucleotides long. The mature miRNA is incorporated into the RNA-induced silencing
complex (RISC) which contains Argonaute (Ago) and is guided to the 3󸀠-UTR of target mRNAs. The gene silencing is achieved by either
mRNA degradation or translational repression.
an altered production of various endothelial vasoactivemedi-
ators, such as nitric oxide, prostacyclin, or endothelin- (ET-)
1, to establish the correct balance between vasoconstriction
and vasodilatation [13–16]. Currently, the management for
PH is aimed at optimizing cardiopulmonary interactions by
targeting prostacyclin, endothelin, and nitric oxide signaling
pathways [17]. The most commonly used treatment regimen
of PH is the use of prostacyclin analogues (Alprostadil,
Epoprostenol, Treprostinil, and Iloprost), endothelin recep-
tor antagonists (Bosentan, Ambrisentan), and inhaled NO.
In addition, phosphodiesterases (PDEs) inhibitors; PDE-
3 inhibitors (e.g., Milrinone and Enoximone), and PDE-5
inhibitors (e.g., Sildenafil and Tadalafil) are used to treat
PH. They were used as an alternative therapeutic strategy
which targets downstream components of the NO signaling
pathway by inhibiting PDE-5, the enzyme that catalyzes the
conversion of cGMP to GMP. Despite the advancement of
modern surgery or PH-specific therapy, the mortality of PH
patients still remains high, ranging between 22.2% and 54.5%
[18].
Although PH (or PAH) is well-studied encompassing
both cardiac and vascular boundaries, the precise cellular and
molecular mechanism of initiation and progression of PH
are not completely understood and are still being explored.
There is no cure of this disease and current therapies are
limited to reverse the vascular remodeling. Evolving evidence
indicates that dysregulation of microRNAs (miRNA or miR)
contributes to PH pathogenesis [19–24]. Indeed, an emerging
body of evidence demonstrates that a fine balance in miRNA
levels seems to be a fundamental to maintaining homeostasis
in the pulmonary vasculature and an imbalance with miRNA
level playing a critical role in the pathogenesis of PH by
regulating a set of targeted genes [25]. This review will
collate vascular remodeling during PH, miRNA biogenesis,
recent advances on miRNA modulation in PH, therapeutic
opportunity, and conclusion.
2. miRNA Biogenesis
The miRNA(s) are composed of a vast family of short,
noncoding RNAs (∼22 nucleotide long). miRNAs are found
from a single cell organism to plant and higher animals and
even viruses [37–39]. In humans, more than 2,500 miRNAs
have been reported in miRBase 20.0 database [40]. The
biogenesis (canonical) pathway of mammalian miRNAs is
a two-step enzymatic process initiated in the nucleus and
then transported to cytoplasm (Figure 1). The transcription
of miRNAs generally processed by RNA polymerase II (less
frequently by RNA polymerase III) and are typically capped
and polyadenylated [41, 42]. As a result, a long primary
miRNA transcripts (pri-miRNA) containing a stem-loop
structure is developed which is recognized by a large protein
complex, called the Microprocessor, the main components
of which are the RNase III Drosha and DiGeorge Syndrome
Critical Region 8 (DGCR8) [43–48] (Figure 1). For most
pri-miRNA, Drosha is contributing the cleavage process
called “cropping” with the assistance of its binding partner
protein, DGCR8 [41, 48, 49]. The resultant product is a
∼60 nucleotides long, hairpin-structured, called precursor
miRNA (pre-miRNA).DGCR8directly interactswith the pri-
miRNA stem and flanking segments, a crucial measurement
for one end of the mature miRNA [45]. In addition to the
canonical pathway of miRNA biogenesis described above,
an alternative pathway also exists that are independent of
Drosha. In alternative pathways, the miRNA can be released
as mitrons (pre-miRNA like introns) [50] from pri-miRNA
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and proceed for miRNA processing unit without assistance
of Microprocessor [50, 51].
The pre-miRNAs are actively transported from the
nucleus into the cytoplasm by Exportin-5 (Exp-5) [52]
(Figure 1). In the cytoplasm, anotherRNase III enzyme, called
Dicer, catalyzing the process with the assistance of partner
molecules Argonaute (Ago2), HIV-1 transactivation response
RNA-binding protein (TRBP) and/or Protein activator of
PKR kinase (PACT), producing a short dsRNA duplex,
miRNA/miRNA∗ of approximately 22-nucleotide length [44,
53–56].ThemiRNA/miRNA∗ duplexes are then incorporated
into a ribonucleoprotein (RNP) complex—called miRISC
(RNA-induced silencing complex)—that plays a critical role
in themiRNA-mediatedmechanism of gene regulation. Dur-
ing assembly process of the miRISC, the miRNA/miRNA∗
duplex is loaded into the Ago, and the strands (called the
“passenger strand”) are released and degraded [57]. Even-
tually, the bound miRNA strand (called the “guide strand”)
dictates miRISC to interact with partially complementary
sequences in target transcripts (localized within the 3󸀠UTR)
and primarily triggersmRNAdeadenylation and degradation
[58].
3. Key miRNA in the Pathogenesis of PH
MicroRNAs (miRNAs) are small, endogenously expressed
noncoding RNAs that regulate gene expression at posttran-
scriptional level, via degradation or translational inhibition
of their target mRNAs [37, 59]. miRNAs are ∼22 nucleotides
in length which bind to the 3󸀠 untranslated region of specific
target genes and thereby suppress/inhibit the translation
of target genes [60, 61]. miRNAs are key regulators of a
wide range of cellular processes and play a pivotal role
in vascular inflammation and cardiovascular pathologies
inclusive of PH. From extensive studies from the past few
years, it has become apparent that miRNAs are expressed in
a cell- and tissue-specific manner and are critically involved
in various biological processes. The degree of imbalances
in their expression may lead to various diseases. Emerging
evidence indicates that miRNAs contribute an important role
in the maintenance of pulmonary vascular homeostasis and
in the pathogenesis of PH [62]. In the following part, a
discussion of the roles of miRNAs in PH-related signaling
pathways is provided.
3.1. miR-21. miR-21 is a ubiquitously expressed miRNA
that is traditionally considered to be an oncogenic miRNA
(oncomiR). The two-channel microarray was performed to
quantify miRNA expression in whole lung extracts during
the development of PH or PAH caused by chronic hypoxia
or monocrotaline in rats. It was suggested that miR-21
expression was downregulated in MCT-induced PH model,
but not in chronic hypoxia rats. The similar change of
miR-21 was observed in cultured PASMCs and PAF. miR-21
showed a similar expression level in both normoxic hypoxic
cells, whereas TGF-𝛽1, an important regulator of pulmonary
vascular remodeling in PH, reduced expression of miR-21.
This suggests that although hypoxia- and monocrotaline-
induced PH shares some common cellular processes driving
the characteristic vascular remodeling, the different patho-
biology induced by hypoxia and monocrotaline may lead to
the different regulation of miR-21 expression. Furthermore,
the downregulation of miR-21 was confirmed in human lung
tissue and serum frompatients with idiopathic PH [20]. Since
BMPs induce smooth muscle cell differentiation through
upregulating the expression of miR-21, the downregulation
of miR-21 in this setting may relate to the reduced BMP
signaling and contribute to the alteration of smooth muscle
cell phenotype in PH [63].
However, Yang and colleagues reported that miR-21
expression was increased in distal small pulmonary arter-
ies of hypoxia-exposed PAH mice and levels of BMPR2,
WWP1, SATB1, and YOD1, the putative miR-21 targets, were
decreased in the same tissue. Transfection of miR-21 mimics
also led to the reduced expression of BMPR2, SATB1, and
YOD1 in PASMCs [23].The crucial role of miR-21 in vascular
pathology has been evidenced by the results that the blockade
of miR-21 impeded the development of intimal hyperpla-
sia after acute vascular injury and bleomycin-induced pul-
monary fibrosis [28, 64]. Yang et al. also found that inhibition
of miR-21 alleviated chronic hypoxia-induced PH and atten-
uated pulmonary vascular remodeling. In human PASMCs,
overexpression of miR-21 promoted, whereas sequestration
of miR-21 abrogated cell proliferation and the expression of
cell proliferation-associated proteins. The miR-21 null mice
showed an exaggerated PH response to hypoxia, suggesting
a major role of miR-21 in the pathogenesis of chronic
hypoxia-induced pulmonary vascular remodeling and PH
[23]. Although an association betweenmiR-21 and PH (PAH)
is identified, the function of miR-21 in the development of
PH is inconsistent in many experimental models. Therefore,
further investigations are required to clarify the role of miR-
21 in the pathogenesis of PH.
3.2. miR-204. The miR-204 appears to be the first miRNA
that showed a mechanistic link between pulmonary arterial
remodeling and cellular function. miR-204 was reported
to be decreased in rodent lungs with hypoxia- and MCT-
induced PAH and lung specimens from patients with PAH
[65].The reports suggested that STAT3 activation contributed
a crucial role in regulating miR-204 in PASMC. It was
further demonstrated that miR-204 inhibition increased
expression of SHP2, triggered the activation of Src kinase,
STAT3, and nuclear factor of activated T cells (NFAT), and
thereby reduced apoptosis and was promoted proliferation
of PASMCs. Finally, delivery of synthetic miR-204 mimic
to the lungs lowered pulmonary artery pressure, reduced
medial wall thickness, normalized levels of miR-204, SHP2,
and STAT3, and alleviated the disease severity [65].This study
may indicate the safe and effective use of mimic delivery to
the pulmonary vasculature for future therapeutic purpose.
Interestingly, Wei et al. have identified reduced level of miR-
204 in the buffy coat of human subjects may correlate with
PAH severity and might serve as a circulatory biomarker for
PH [66].
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3.3.miR-143/145Cluster. ThemiR-143/145 clusterwas consid-
ered to be expressed specifically in vascular smooth muscle
cells [67]. Expression of miR-143/145 was driven by TGF-𝛽
and BMP4 and induced contractile gene expression through
downregulating KLF4 and myocardin [31, 68, 69]. The ele-
vated levels of miR-145 were observed in primary PASMCs
cultured frompatients with BMPR2mutations and also in the
lungs of BMPR2-deficient mice, suggesting a role of BMPR2
signaling inmodulatingmiR-145 expression [24]. Caruso and
colleagues also found that miR-145 was downregulated in
patient samples obtained from idiopathic and congenital PH
but upregulated in plexiform lesions. The role of miR-145 in
PAH was further explored and elevated expression of miR-
145 was shown in the wild type mice exposed to hypoxia.
miR-145 deficiency and a locked nucleic acid anti-miR-145
resulting in significant protection from hypoxia-induced PH
may represent a potential therapeutic target [24].
3.4. miR-17-92 Cluster. The miR-17-92 cluster encodes seven
related miRNAs, which result from the transcription of a
single pre-miRNA and is further processed and cleaved to
the mature miRNAs [70]. miR-17-92 cluster was retrieved
as potential modulators of BMPR2 signaling by performing
a computational algorithm on the BMPR2 gene. Overex-
pression of miR-17-92 resulted in a marked reduction of
BMPR2 protein level, and BMPR2 was proved to be directly
targeted by miR-17 and miR-20a by using a BMPR2 reporter
in HEK293 cells. STAT3 was found to be involved in IL-
6 signaling-mediated upregulation of miR-17-92 cluster and
the subsequent downregulation of BMPR2, since a highly
conserved STAT3-binding site exists in the promoter region
of miR-17-92 gene [71].
The role of a cholesterol-modified antagomir to miR-20a
in hypoxia-induced PH was explored by Brock et al. miR-
20a restored functional BMPR2 signaling in human PASMCs
and intraperitoneal administration of anti-miR-20a increased
BMPR2 levels and alleviated vascular remodeling in lung
tissue of hypoxic mice [72]. Antagomirs to miR-17 and miR-
92a reduced muscularization of pulmonary arteries in the
hypoxicmouse andmonocrotaline ratmodels of PH, but only
anti-miR-17 decreased RVSP and parameters of right heart
dysfunction [22].
3.5. miR-130/301. Bertero and colleagues identified miR-
130/301 family as a master regulator of cellular prolifera-
tion in PH by constructing in silico a network of genes
and interactions based on curated seed genes with known
importance in PH. miR-130/301 expression was found to
be increased in lungs of mice suffering from PH induced
by SU5416 administration with chronic hypoxia, in lungs
of rats with MCT-induced PH and in lungs of juvenile
sheep with shunt-induced PH. In both human PAECs and
PASMCs, multiple PH inducers, including hypoxia, IL-1𝛽,
and IL-6, increased miR-130/301 expression and hypoxia was
found to upregulate miR-130/301 via a dependence on HIF-
2𝛼 and POU5F1/OCT4. It was further validated that miR-
130/301 modulated apelin-miR-424/503-FGF2 signaling in
PAECs andmiR-130/301-PPAR-𝛾 axis controlled proliferation
of PASMCs by increasing STAT3 expression and activity
and repressing miR-204 expression. In hypoxia-induced PH
mouse model, induction of miR-130/301 was promoted while
miR-130/301 inhibition prevented PH pathogenesis [73].
4. miRNA in PASMCs Plasticity in PH
PH is broadly considered to be a vascular disease as vaso-
constriction in the pulmonary artery is a prime cause for
the development of PH.The hyperproliferation of pulmonary
vascular cells (mainly VSMC) and subsequent neointima
formation in the small PAs are hallmark in PH. On the other
hand, pulmonary arterial endothelial cells (PAECs) further
contribute a critical role in vascular homeostatic balance in
the pulmonary vascular bed by orchestrating the vessel tone,
leucocytes trafficking, and so forth [74, 75]. Another cell type
called adventitial fibroblasts also participate a critical role in
PH [76]. Proliferation of fibroblasts is reported in hypoxia-
induced PH that plays a role in adventitial thickening [77, 78].
Under pathological situation like PH (PAH), the endothe-
lium becomes dysfunctional which allows the penetration of
infiltrating molecules, increased leucocytes adhesion, getting
resistant to apoptosis that result in severe remodeling in the
pulmonary vessels. These infiltrating molecules invade the
barrier of neighboring cells like smooth muscle cells and
activating the resident of adventitious fibroblasts.The remod-
eling process is basically an interaction between these cell-
types present in the pulmonary arterial layers that resulting
in amarked histological change in the pulmonary vasculature
[75]. An emerging body of evidences suggests that the
miRNAs play a pivotal role in the vascular cell integrity and
plasticity during the progression of PH. Here, we assemble
those miRNAs that participate in vascular remodeling in PH.
Although identification of miRNAs in vascular diseases
like PH is relatively new, but the earliest association con-
necting VSMC remodeling with miRNAs was reported in
2007. Ji et al. described the miRNA signature in the vascular
wall of balloon-injured carotid artery rat model [64]. They
showed that miR-21 was upregulated and the cellular effects
were targeted by PTEN and Bcl
2
for neointimal lesion
formation [64]. The initial studies of miR-21 in vascular
remodeling were followed by series of milestone works that
include miR-143/145 cluster [24, 31, 79–83]. Two of the key
miRNAs involved in regulation of the phenotype of SMCs are
miR-143 and miR-145. miR-145 is transcribed bicistronically
along with miR-143 from human chromosome 5 [24]. With
relevance to PAH, downregulation of miR-145 is associated
with increased proliferation of neointimal cells [31]. Down-
regulation of target genes klf4 and klf5 by activation of
miR-143/miR-145 upregulates SMC-specific genes such as
SMA, calponin, and SM22-𝛼, triggering differentiation and
lowering the proliferation rates in vascular SMCs [31, 82].
Another miRNA, miR-221/222 that triggers PDGF signaling
in VSMC is thought to contribute in neointimal proliferation
[35, 84, 85]. It is demonstrated that inhibition of miR-
221 prevented PDGF induced proliferation, while forced
expression of miR-221 increased proliferation and reduced
the expression of VSMC marker [35, 84].
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Table 1: Vascular smooth muscle cells and miRNA modulation.
miRNA Function Target gene(s) Reference
miR-1 Promote VSMC differentiation Myocardin, KLF4 [26, 27]
miR-21 Promote VSMC differentiation PDCD4 [28]
miR-24 VSMC proliferation and repression of contractile gene expression Tribbles-like protein 3, SMURF1 [29]
miR-26a Promote VSMC dedifferentiation Smad1 and Smad4 [30]
miR-143/145 Promote VSMC differentiation KLF4, KLF5, ELK1, versican, BMP4, MRTF [31–33]
miR-146 Promote VSMC dedifferentiation and proliferation KLF4 [34]
miR-221/222 Promote VSMC dedifferentiation and proliferation p27Kip, c-kit [35, 36]
In addition to the above miRNAs, other miRNAs are
reported to regulate SMC gene expression in hypoxia-
induced PH.They included miR-210, miR-124, miR-204, and
miR-138. It is demonstrated that miR-210 that acts as a
hypoxia-inducible miRNA both in vitro and in vivo, inhibits
PASMC apoptosis in hypoxia by specifically repressing E2F3
[86]. A cell-based high throughput screening of a human
miRNA library with the NFAT luciferase reporter system
identified miR-124 as a new candidate in PH. It showed
decreased NFAT reporter activity and, decreased dephos-
phorylation and the nuclear translocation of NFAT [87].
An elegant study by Courboulin et al. demonstrated that
miR-204 downregulation correlates with PH severity and
responsible for proliferative and antiapoptotic phenotypes of
PH-PASMCs targeting STAT3 and NFATc [65]. Interestingly,
a recent study showed that a serine/threonine kinase Mst1,
a modulator of cell death, appears to be a target of miR-138
[88]. The authors suggest that miR-138 may be a negative
regulator of PASMC apoptosis in hypoxic mediated PAH. A
panel of miRNAs which are shown tomodulate SMC fate and
modulation are listed in Table 1 [26–36].
5. miRNA as Therapeutic Target for PH
Therapeutic target which defines the treatment of a disease by
means of a well-defined biological molecule. In this regard,
miRNAs, a “tiny” RNA molecule, have become an important
gene modulator of various biochemical, physiological, and
cellular functions. As we observed that either deficiency or
abundance of a specific miRNA or cluster of miRNAs con-
tributed a pathological state of many cardiovascular diseases
including PH, it is reasonable to accept thosemiRNAs as ther-
apeutic target for diagnosis and therapeutic intervention.This
is because we can utilize ability of a single miRNA to control
the expression of multiple (hundreds) proteins suggest that
changes of a single miRNA may influence several signaling
pathways associated with pathological disease state. While
each target is regulated subtly, the additive effect of coordi-
nated regulation of a large suite of transcripts is believed to
result in strong phenotypic outputs. Several animal models
in diverse disease pathology showed usefulness ofmiRNAs as
targetmolecules for therapeutic benefit; this reviewwill focus
on vascular remodeling associated with PH. At therapeutic
strategic stand-point, the aberrant miRNA expression can be
modulated or restored to normal by two main approaches:
an anti-miRNA (anti-miR) and miRNA mimic. The former
can be applicable to those miRNAs whose expressions were
increased in disease pathology and, therefore, silencing or
inhibiting will be beneficial. Tomodulate miRNA expression,
the current strategy utilized chemicallymodified, cholesterol-
conjugated single-stranded RNA analogues complementary
to the mature miRNAs for antagomir or mimics, respec-
tively [89]. Synthetic modified oligonucleotides are currently
used as potential “antagomirs” for miRNA silencing [90].
An elegant work demonstrated by Liu et al. in a balloon-
injury model represents a successful knocking down of miR-
221/222 that suppressed VSMC proliferation and neointimal
lesion formation [35]. Recently, Brock et al. have shown that
treatment with antagomiR-20a restores the levels of BMPR2
in pulmonary arteries and prevents vascular remodeling in
hypoxia-induced PAH [72]. For downregulated miRNAs, a
mimic approach is generally undertaken which basically res-
cued the underexpressed miRNA in the tissue under patho-
logical situation [89].This strategy is sometimes referred to as
miRNA replacement as it reintroduced the similar depleted
miRNA those were downregulated during diseases progres-
sion.Therefore, by introducing the miRNA “mimic,” the cells
can restore the function as the miRNA “mimic” is expected
to target the same set of mRNAs that is also regulated by
the endogenous miRNA. In a very comprehensive study by
Courboulin et al., they demonstrated that reestablishing of
miR-204 level by delivery of synthetic miR-204 into the
lungs of experimentally-induced PAH animals significantly
reduced the disease pathology [65].
Although the miRNA-based intervention is attractive
and seems to be feasible, however, several challenges are
noted. First, the critical miRNAs responsible for PH must
be confirmed definitively in well-accepted animal models
along with explanted human PAH samples, biopsies, and
so forth, second, the cellular, molecular and physiological
function of these miRNAs should be performed in diseases
progression and prevention; third, the delivery route should
be precisely targeted or restricted to lung vascular cells, for
example, PAEC, PASMC, or fibroblasts. This will minimize
the off-target effects on the neighboring cells. Finally, the
dose of antagomir or mimic delivery to the vascular bed
should be carefully monitored further to avoid off-target
effects. Therefore, our future direction should be focus of
vascular cell-specific delivery of miRNAmimic or inhibitors.
Additionally, a regulated release of miRNAs by conjugat-
ing nanoparticle will be considered for long-term use.
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Finally, miRNA-mediated therapeutics can be achieved by
inhalation which may reduce the potential off-target issues
to the other organs.
6. Can Circulatory miRNA Be Used as
a Biomarker in PH?
Biomarker generally refers to measurable substance in bio-
logical state. At clinical stand-point, it is extremely important
as it predicts the “medical” outcome of a disease and its pro-
gression. Over the past few years, it has been demonstrated
that miRNAs are found in the blood, plasma, urine, platelets,
and saliva in a surprisingly stable form [91–97]. The stability
of miRNA in the extracellular environment offers a great
opportunity to consider as “biomarker” at clinical settings.
Using miRNA as a “biomarker” offers many advantages like
early prediction of diseases, differential expression during
disease progression/pathologies, high degree of specificity,
and sensitivity and importantly having longer half-life in the
system. Accumulating evidence suggested that the stability
of miRNA in extracellular environment illustrated by packed
with lipid vesicles, wrapped in protein or lipoprotein com-
plexes [98–100]. In the context of cardiac diseases that include
myocardial infarction, hypertrophy and heart failure; several
miRNAs are identified and predicted to be considered as
“biomarker” [101–104].
The miRNAs are circulating freely in the mammalian
blood and can be predicted as “biomarker” for early diagnosis
of cardiovascular diseases in humans [102, 105–108]. Several
evidences indicate thatmiRNAs are secreted asmicro vesicles
or exosome and apoptotic bodies that may be responsible
for release the miRNAs into the circulation [109–112] and
are extremely stable in the blood or serum [91]. Rhodes
and colleagues measured plasma levels of miRNAs in eight
patients newly diagnosed with PAH and eight healthy con-
trols by use of microarray analysis. Fifty-eight miRNAs
showed differences in plasma concentration between the
two groups and miR-150 was largest downregulated in PAH.
Reduced expression of miR-150 predicted 2-year survival and
correlated with disease severity. The miR-150 level was also
found to be significantly reduced in circulating microvesicles
and lymphocytes from patients with PAH [113]. Courboulin
et al. reported that downregulation of miR-204 in buffy-coat
cells correlated with PAH severity and might serve as a cir-
culatory biomarker of PAH [65]. On the contrary, increasing
higher plasma levels of miR-130/301 family members were
observed in patients with increasing hemodynamic severity
of PH [73].
Our previous study detected the pattern of miRNAs in
buffy-coat samples from mild-to-severe human PH subjects
compared with the control subjects by miRNA array. Our
study revealed that moderate to severe PH in human subjects
are associated with significant downregulation of plasma
levels of circulatory miR-1, miR-26a, and miR-29c. The
kinetics of the changes differed from moderate to severe
PH human subjects as we observed further downregulation
of the above miRNAs in severe PH. We also found a set
of upregulated miRNA in the circulation of PH subjects.
miR-21, miR-23b, miR-130a, miR-491, and miR-1246 were
moderately upregulated in moderate PH subjects and were
more pronounced in severe PH. Another set of miRNAs that
include miR-133b, miR-204, and miR-208b were significantly
upregulated in all moderate PH subjects and showed further
increment in severe PH subjects [66]. Our study provided
the evidence for the first time that circulating miRNAs in the
setting of PH may be used as early detection parameters for
PH. Nevertheless, the data presented were based on limited
study population and the results need to be confirmed in a
larger cohort study. Furthermore, the dysregulation miRNA
in PH remains to be testedwhether these circulatorymiRNAs
have any influence in the target genes.
Circulatory miRNAs are considered to be novel promis-
ing biomarkers for detection of PH.However, at current stage,
using circulatory miRNA as diagnostic tool for detecting PH
is still in its infancy.The key advantage of circulatingmiRNAs
is a noninvasive testing procedure and relies on the stability
of miRNAs in the circulation and their storage condition.We
give credit to the concept of quick determination of secretory
molecules (miRNAs) in the blood; but the importance of
miRNAmust be reevaluated at the clinical setting ormodel at
multiple laboratories. Another limitation is the small number
of cohort study which appears to be heterogeneous clinical
sample-type. These points may consider as preliminary-type
of observation and need further confirmatory studies for
considering miRNAs as biomarkers for clinical use.
7. Conclusion
Understanding of miRNAs role and function in the pul-
monary circulation will offer and contribute a great potential
to the pathogenesis of PH or PAH. The miRNA signature
can be used as a diagnostic tool for the development of
therapeutic strategy. The characterization of these miRNAs
under various experimental settings (in vitro and in vivo)
should be performed alongwith the human subjects.The out-
come will validate both physiological and pathological roles
of these miRNAs during the development and progression
of PH prior to consider them for therapeutic intervention
or future clinical trials. Furthermore, use of disease specific
mouse models, conditional transgenic, and knockouts are
necessary to elucidate the functional role in vivo and ver-
ify its therapeutic potential, both of which remain largely
unexplored. More novel approaches such as combination of
Argonaute protein immunoprecipitation, deep sequencing,
or proteomic profiling approaches are required to identify
its potential bona fide targets responsible for its functional
impact.
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